Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX - Delayed Quote AUD

SomnoMed Limited (SOM.AX)

Compare
0.5300
+0.0100
+(1.92%)
At close: April 4 at 4:10:37 PM GMT+11
Loading Chart for SOM.AX
  • Previous Close 0.5200
  • Open 0.5300
  • Bid 0.4500 x --
  • Ask 0.5300 x --
  • Day's Range 0.5200 - 0.5400
  • 52 Week Range 0.1900 - 0.6950
  • Volume 55,900
  • Avg. Volume 66,786
  • Market Cap (intraday) 114.537M
  • Beta (5Y Monthly) 1.05
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date Feb 28, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.80

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. In addition, it provides Sunrise, a bio-signal to diagnose sleep apnea. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.

somnomed.com/au/

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: SOM.AX

View More

Performance Overview: SOM.AX

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

SOM.AX
15.22%
S&P/ASX 200 [XJO] (^AXJO)
6.02%

1-Year Return

SOM.AX
77.89%
S&P/ASX 200 [XJO] (^AXJO)
1.36%

3-Year Return

SOM.AX
71.76%
S&P/ASX 200 [XJO] (^AXJO)
2.05%

5-Year Return

SOM.AX
49.62%
S&P/ASX 200 [XJO] (^AXJO)
51.31%

Compare To: SOM.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SOM.AX

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    114.54M

  • Enterprise Value

    101.95M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.88

  • Price/Book (mrq)

    2.41

  • Enterprise Value/Revenue

    1.02

  • Enterprise Value/EBITDA

    33.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.98%

  • Return on Assets (ttm)

    -2.14%

  • Return on Equity (ttm)

    -15.51%

  • Revenue (ttm)

    100.25M

  • Net Income Avi to Common (ttm)

    -6M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.5M

  • Total Debt/Equity (mrq)

    12.45%

  • Levered Free Cash Flow (ttm)

    923.07k

Research Analysis: SOM.AX

View More

Company Insights: SOM.AX

Research Reports: SOM.AX

View More

People Also Watch